What is it about?
Overview of data on the following compounds: aztreonam/avibactam, cefepime/enmetazobactam, cefepime/taniborbactam, cefepime/zidebactam, cefiderocol, ceftaroline/avibactam, ceftolozane/tazobactam, ceftazidime/avibactam, imipenem/relebactam, meropenem/nacubactam and meropenem/vaborbactam
Featured Image
Photo by CDC on Unsplash
Why is it important?
Provides a pragmatic overview on the new BL/BLIs and cefiderocol
Perspectives
New antibiotics against resistant Gram-negative bacteria arrive quickly, and keeping up with their spectrum, pharmacology and clinical data is hard even for specialists. Together with microbiologists, pharmacologists and clinicians from several Italian centres, we wanted to build a single, practical guide that can be consulted at the bedside.
Professor Stefano Di Bella
Universita degli Studi di Trieste
Read the Original
This page is a summary of: Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians, December 2023, Authorea, Inc.,
DOI: 10.22541/au.170259036.66886277/v1.
You can read the full text:
Contributors
The following have contributed to this page







